// App-Quantinova.ai

: CAPTAIN: Effects of triple therapy on FEV1 response in patients with inadequately controlled asthma on ICS/LABA

Researchers

Presenter

  • Huib A.M. Kerstjens

Principal Investigators

  • Carl Abbott

  • Louis-Philippe Boulet

  • Sarah Chang

  • Geoffrey Chupp

  • Jodie Crawford

  • Nicola A. Hanania

  • Robert Nathan

  • John Oppenheimer

  • Emilio Pizzichini

  • Hironori Sagara

  • William Busse

Medical Centers

  • Rutgers New Jersey Medical School, Newark, NJ, United States of America

  • NIH/NIEHS, Research Triangle Park, United States of America

  • GSK, Brentford, Middlesex, United Kingdom,

  • University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States

  • Asthma & Allergy Associates, P.C. and Research Center (at the time of the study), Colorado Springs, CO, United States of America

  • The Jikei University School of Medicine, Tokyo, Japan

  • University of Groningen and University Medical Center Groningen, Groningen, Netherlands

  • Baylor College of Medicine, Houston, Texas, United States

  • GSK & Federal University of Santa Catarina, Brentford, Middlesex & Santa Catarina, United Kingdom

  • Yale Center for Asthma and Airway Disease, Yale School of Medicine, New Haven, CT, United States of America

  • Laval University, Quebec, Quebec, Canada.

Locations

  • United States

  • Canada

  • United Kingdom

  • Netherlands

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Umeclidinium

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Controlled

  • Parallel Group

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved